|Support type:||Scholarships in Brazil - Scientific Initiation|
|Effective date (Start):||July 01, 2012|
|Effective date (End):||December 31, 2012|
|Field of knowledge:||Health Sciences - Medicine - Pathological Anatomy and Clinical Pathology|
|Principal researcher:||Luiz Felipe Domingues Passero|
|Grantee:||Jéssica Adriana de Jesus|
|Home Institution:||Faculdade de Medicina (FM). Universidade de São Paulo (USP). São Paulo , SP, Brazil|
The antigens released by parasites are interesting targets for the development of vaccine candidates, as are the first molecules to interact with the innate immune system and establish an intrinsic physiological interaction with the host cell.Therefore, these antigens have been targets for the development of vaccines against cutaneous leishmaniasis, visceral canine and murine, respectively.Even with the recent publication of the secretome of Leishmania donovani has become possible to develop better defined vaccine candidates against this tropical disease, however, a factor that limits their development is the efficiency of this type of antigen for further purification.Thus, DNA vaccines become good way to overcome this problem the protein purification, since the target proteins are expressed in vivo.In this proposal, will analyze the cellular and humoral immune responses of BALB / c mice immunized with pVAX1 plasmid containing the gene encoding the antigen iron superoxide dismutase of L. (L.) amazonensis. BALB / c mice are immunized with the DNA vaccine three times at intervals of 15 days intramuscularly. After 7 days the last vaccination, serum, lymph nodes and spleen of animals will be collected.A cell suspension is produced from the lymphoid organs, which will be released and stimulated with antigen for a total period of 72h. After this period the analysis of IL-4, IL-10, IL-12, IFN-gama, and TNF-alfa is analyzed.The levels of total IgG, IgG1 and IgG2 anti-Leishmania be evaluated in the serum of experimental animals.This project aims to contribute to the IC understanding the action of DNA vaccines produced against Cutaneous Leishmaniasis in an experimental murine infection.